NSE
AARTIDRUGS

Aarti Drugs Limited

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Aarti Drugs Limited Stock Price

Vitals

Today's Low:
₹580
Today's High:
₹616.35
Open Price:
₹612.95
52W Low:
₹310.8
52W High:
₹645
Prev. Close:
₹611.95
Volume:
333534

Company Statistics

Market Cap.:
₹56.48 billion
Book Value:
128.772
Revenue TTM:
₹27.55 billion
Operating Margin TTM:
9.97%
Gross Profit TTM:
₹6.19 billion
Profit Margin:
6.52%
Return on Assets TTM:
6.95%
Return on Equity TTM:
14.93%

Company Profile

Aarti Drugs Limited had its IPO on under the ticker symbol AARTIDRUGS.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Aarti Drugs Limited has a staff strength of 1,003 employees.

Stock update

Shares of Aarti Drugs Limited opened at ₹612.95 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹580 - ₹616.35, and closed at ₹582.6.

This is a -4.8% slip from the previous day's closing price.

A total volume of 333,534 shares were traded at the close of the day’s session.

In the last one week, shares of Aarti Drugs Limited have slipped by -1.9%.

Aarti Drugs Limited's Key Ratios

Aarti Drugs Limited has a market cap of ₹56.48 billion, indicating a price to book ratio of 3.8106 and a price to sales ratio of 1.6028.

In the last 12-months Aarti Drugs Limited’s revenue was ₹27.55 billion with a gross profit of ₹6.19 billion and an EBITDA of ₹3.26 billion. The EBITDA ratio measures Aarti Drugs Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Aarti Drugs Limited’s operating margin was 9.97% while its return on assets stood at 6.95% with a return of equity of 14.93%.

In Q2, Aarti Drugs Limited’s quarterly earnings growth was a positive 37.9% while revenue growth was a positive 6.3%.

Aarti Drugs Limited’s PE and PEG Ratio

Forward PE
0
Trailing PE
31.4544
PEG

Its diluted EPS in the last 12-months stands at ₹19.39 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aarti Drugs Limited’s profitability.

Aarti Drugs Limited stock is trading at a EV to sales ratio of 1.8145 and a EV to EBITDA ratio of 14.627. Its price to sales ratio in the trailing 12-months stood at 1.6028.

Aarti Drugs Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 7.51%.

Balance sheet and cash flow metrics

Total Assets
₹24.21 billion
Total Liabilities
₹9.33 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
7.51%

Aarti Drugs Limited ended 2024 with ₹24.21 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹24.21 billion while shareholder equity stood at ₹11.92 billion.

Aarti Drugs Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹9.33 billion in other current liabilities, in common stock, ₹10.21 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹89.60 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹2.05 billion.

Aarti Drugs Limited’s total current assets stands at ₹14.92 billion while long-term investments were ₹0 and short-term investments were ₹122.10 million. Its net receivables were ₹8.65 billion compared to accounts payable of ₹4.80 billion and inventory worth ₹5.16 billion.

In 2024, Aarti Drugs Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Aarti Drugs Limited paid ₹0.08 in dividends in 2024.

Other key metrics

Current Trading Price
₹582.6
52-Week High
₹645
52-Week Low
₹310.8
Analyst Target Price

Aarti Drugs Limited stock is currently trading at ₹582.6 per share. It touched a 52-week high of ₹645 and a 52-week low of ₹645. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹555.09 and 200-day moving average was ₹455.75 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 6498.6% of the company’s stock are held by insiders while 607.3% are held by institutions.

Frequently Asked Questions About Aarti Drugs Limited

The stock symbol (also called stock or share ticker) of Aarti Drugs Limited is AARTIDRUGS

The IPO of Aarti Drugs Limited took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
₹113.35
-0.65
-0.57%
₹7.99
-0.41
-4.88%
₹1079.5
-53.4
-4.71%
₹1.6
-0.05
-3.03%
Gati Limited (532345)
₹160.2
-0.4
-0.25%
₹15.72
-0.71
-4.32%
₹688.5
-56.4
-7.57%
₹352.55
-13
-3.56%
₹1.66
0.14
+9.21%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Aarti Drugs Limited, through its subsidiaries, engages in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company provides APls in various therapeutic areas, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer’s treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, para toluene sulphonic acid methyl ester, N,N’,N’-tris-(4-toluene sulfonyl)-diethylenetriamine, sodium para toluene sulfinate, para toluene sulphonyl hydrazide, di-phenyl sulphone, formamide, ammonium sulfate, and calcium fluoride, as well as benzene sulphonic acid sodium salt, benzyl nicotinate, methyl nicotinate, ethyl para toluene sulphonate, N-methyl methane sulfonamide, benzene sulphonamide, 2-phenoxy methane sulphanilide, para toluene sulfonamides, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, and N-methyl methane sulfonamides. In addition, the company’s development products portfolio comprises Itraconazole and Fluconazole for antifungal applications; Dabigatran for use as an anticoagulant; Ticagrelor for cardiovascular diseases; Sitagliptin for use as an antidiabetics; and Alpha Lipoic Acid for application as an antioxidants. Further, it provides contract manufacturing services. Aarti Drugs Limited was incorporated in 1984 and is headquartered in Mumbai, India.

Address